0 239

Cited 72 times in

Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck

 Gwi Eon Kim  ;  Sang-wook Lee  ;  Sei Kyung Chang  ;  Hee Chul Park  ;  Hong Ryull Pyo  ;  Joo Hang Kim  ;  Sun Rock Moon  ;  Hyeong Sik Lee  ;  Eun Chang Choi  ;  Kwang Moon Kim 
 RADIOTHERAPY AND ONCOLOGY, Vol.61(3) : 261-269, 2001 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Combined Modality Therapy ; Female ; Head and Neck Neoplasms/drug therapy* ; Head and Neck Neoplasms/pathology ; Head and Neck Neoplasms/radiotherapy* ; Humans ; Lymphoma/drug therapy* ; Lymphoma/pathology ; Lymphoma/radiotherapy* ; Male ; Middle Aged ; Prognosis ; Radiotherapy Dosage ; Remission Induction ; Retrospective Studies ; Survival Rate
Chemotherapy ; Radiotherapy ; Angiocentric lymphoma ; Head and neck
BACKGROUND AND PURPOSE: To clarify the clinical benefit derived from the combined modality therapy (CMT) comprised of chemotherapy and involved-field radiotherapy (XRT) for stage I and II angiocentric lymphomas of the head and neck. MATERIAL AND METHODS: Of 143 patients with angiocentric lymphoma of the head and neck treated at the Yonsei Cancer Center between 1976 and 1995, 104 patients (XRT group) received involved-field XRT alone with a median dose of 50.4 Gy (range: 20-70 Gy), while 39 patients (CMT group) received a median three cycles (range: 1-6 cycles) of chemotherapy before starting involved-field XRT. The response rate, patterns of failure, complications, and survival data of the XRT group were compared with those of the CMT group. RESULTS: Despite a higher response rate, local failure was the most common pattern of failure in patients of the both groups. The patterns of failure, including the systemic relapse rate were not influenced by the addition of combination chemotherapy. Although both modalities were well tolerated by the majority of patients, aberrant immunologic disorders or medical illnesses, such as a hemophagocytic syndrome, sepsis, intractable hemorrhage, or the evolution of second primary malignancies were more frequently observed in patients of the CMT group. The prognosis of patients in the XRT group was relatively poor, with a 5-year overall actuarial survival rate of 38% and disease-free survival rate of 32%, respectively. However, their clinical outcome was not altered by the addition of systemic chemotherapy. Achieving complete remission was the most important prognostic factor on univariate and multivariate analyses, but treatment modality was not found to be a prognostic variable influencing survival. CONCLUSIONS: Involved-field XRT alone for angiocentric lymphoma of the head and neck was insufficient to achieve an improved survival rate, but the combination of chemotherapy and involved-field XRT failed to demonstrate any therapeutic advantage over involved-field XRT alone.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Gwi Eon(김귀언)
Kim, Joo Hang(김주항)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.